港安健康国际医疗介绍,与单用Ipilimumab相比,Nivolumab(Opdivo)作为单药或与Ipilimumab(Yervoy)联合治疗晚期黑色素瘤患者10年后的总生存期(OS)和黑色素瘤特异性生存期(MSS)都有显著而持久的改善,该结果同时发表在《新英格兰医学杂志》上。
因此,这一研究结果将进一步推进ipilimumab和nivolumab联合抗癌的临床应用,在评估黑色素瘤患者脑转移的情况的同时,尽早应用这一联合抗癌的疗法或许更能使患者收益。 参考文献: Hussein A. Tawbi, Peter A. Forsyth, Alain Algazi. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain 别睡了!睡眠太...
在Nivolumab+Ipilimumab治疗组中,87%的患者(n=102)的最佳肿瘤负荷减少率达到或超过80%,72%的患者(n=55)的最佳肿瘤负荷减少率介于50%和80%之间;在单用Nivolumab治疗组中,88%的患者(n=85)和75%的患者(n=32)出现了这些情况;在单用Ipilimumab治疗组中,80%的患者(n=24)和40%的患者(n=17)出现了这些情况。
5. Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in CheckMate 067. J Clin Oncol. 2023;41(suppl 16):9542. doi:10.1200/JCO.2023....
黑色素瘤治疗新组合 --- N i v o l u m a b 和 Ipilimumab[ J]. 临床药物治疗杂志, 2017, 15(1): 79-84. ZHANG Min, ZHONG Wu. New combination of melanoma treatment: nivolumab and ipilimumab[ J]. Clinical Medication Journal, 2017, 15(1): 79-84.张珉;钟武.黑色素瘤治疗新组合——Nivo...
The optimal use of immunotherapy is not well defined in melanoma. Available frontline options, such as the combination of ipilimumab and nivolumab, may be too toxic for all patients, and although PD-1 inhibitors have a high response rate, patients will ultimately develop resistance. As such...
See how OPDIVO® (nivolumab) performed, alone or in combination with YERVOY® (ipilimumab), in clinical trials for people with melanoma skin cancer that has spread or cannot be removed by surgery. Please see Indication and Important Safety Informatio
December 16, 2020 — The combination of nivolumab with ipilimumab demonstrated activity in patients with metastatic uveal melanoma with encouraging responses.
Anna C. Pavlick, MD, associate professor, co-director, Melanoma Program, assistant director, Clinical Research Education, discusses a study that examined two immunotherapy agents, ipilimumab and nivolumab, in patients with melanoma. Recent Videos Insights From Latest Research and Trials Advancing Myel...
Prior to the use of nivolumab/ipilimumab combination, the 1-year survival rate for patients with MBM was 20%.1“Inducing an intracranial response with combination immunotherapy has a direct and lasting impact on survival for patients whose melanoma has spread to the brain,” said Tawbi. “We...